Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC
Laura M. Spring(Massachusetts General Hospital), Leif W. Ellisen(Harvard University), Veerle Bossuyt(Harvard University), Beverly Moy(Massachusetts General Hospital), Bogang Wu(George Washington University), Jacob Geisberg(Harvard University), Mengran Zhang(Harvard University), Nicole Peiris(Harvard University), Siang‐Boon Koh(Harvard University), Aditya Bardia(Harvard University), Lianne Ryan(Harvard University), James T. Coates(Harvard University), Sara M. Tolaney(Dana-Farber Cancer Institute), Simona Cristea(Harvard University), Franziska Michor(Harvard University), Steven J. Isakoff(Harvard University), Ting Liu(Harvard University), Rachel O. Abelman(Massachusetts General Hospital)
Cited by 2
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983